Institutional Investors Lead Shift in Anadarko Petroleum Corp (NYSE:APC) Sentiment

Lloyd Doyle
January 13, 2018

(NYSE:APC) by 9.5% during the 3rd quarter, according to its most recent disclosure with the SEC.

Anadarko Petroleum announced that its board has initiated a stock buyback program on Wednesday, September 20th that authorizes the company to repurchase $2.50 billion in outstanding shares.

The stock decreased 1.09% or $0.02 during the last trading session, reaching $1.82. Fis Group Inc. bought a new position in Anadarko Petroleum in the third quarter worth $107,000. ET AL lifted its position in Anadarko Petroleum by 0.8% during the second quarter. Also, the number of investment professionals holding Anadarko Petroleum Corp in their top 10 positions was flat from 7 to 7 for the same number.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Finally, Gillespie Robinson & Grimm Inc. lifted its holdings in Anadarko Petroleum by 26.2% in the fourth quarter.

Taking a deeper look into the technical levels of Anadarko Petroleum Corp (APC), we can see that the Williams Percent Range or 14 day Williams %R now sits at -4.70. (APC) traded up $3.09 on Thursday, hitting $58.50. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.03 and a current ratio of 2.03. The stock has a market capitalization of $32,270.00, a price-to-earnings ratio of -16.66 and a beta of 1.38. The Return on Assets for Anadarko Petroleum Corporation (NYSE:APC) is -0.043024.

For the current quarter, 31 analysts are projecting a mean EPS of $-0.01/share. The firm had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.52 billion. The RSI computes momentum as the ratio of higher closes to lower closes: stocks which have had more or stronger positive changes have a higher RSI than stocks which have had more or stronger negative changes. About 2.69 million shares traded.

The company's stock is now moving with a +ve distance from the 200 day SMA of approximately 18.75%, and has a solid year to date (YTD) performance of 9.06% which means that the stock is constantly adding to its value from the previous fiscal year end price. Grassi Invest holds 0.15% or 17,975 shares in its portfolio. Shareholders of record on Wednesday, December 13th were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.34%. Anadarko Petroleum's dividend payout ratio is presently -5.65%.


A number of brokerages have weighed in on APC.

In order to tell which way a stock is trending, the stock's share price should be compared to its moving average. Cowen set a $60.00 price target on Anadarko Petroleum and gave the company a "buy" rating in a report on Monday, October 16th.

COPYRIGHT VIOLATION WARNING: "Anadarko Petroleum's (APC) Buy Rating Reiterated at Piper Jaffray Companies" was first published by StockNewsTimes and is owned by of StockNewsTimes. Old Mutual Customised Solutions (Proprietary) holds 0.08% of its portfolio in Anadarko Petroleum Corporation (NYSE:APC) for 12,300 shares. Argus Research has "Buy" rating and $105 target.

According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 1.73 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell.

Zoetis Inc. (NYSE:ZTS) is holding above the stock's moving averages, indicating a postitive uptrend for Healthcare company. "(APC)" was posted by The Lincolnian Online and is owned by of The Lincolnian Online. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/12/chelsea-counsel-co-sells-34865-shares-of-anadarko-petroleum-co-apc.html. Anadarko Petroleum Corporation (NYSE:APC) has risen 8.29% since January 12, 2017 and is uptrending. The Company is engaged in developing, acquiring, and exploring for oil and natural-gas resources. It operates through three divisions: Oil and Gas Exploration and Production, Midstream, and Marketing.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER